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BMC Pharmacology and Toxicology was created from the merger of two journals within the BMC series published by
BioMed Central: BMC Pharmacology and BMC Clinical Pharmacology. BMC Pharmacology operated anonymous peer
review whereas BMC Clinical Pharmacology operated a fully open peer review policy where the identity of the
reviewers was known to the editors, authors and readers. The merged journal also adopted a fully open peer
review policy. Two years on we discuss the views and experiences of our Editorial Board Members towards open
peer review on this biomedical journal.The story so far
The BMC series of journals was established in 2000 by
BioMed Central to provide open access to research pub-
lished across a range of disciplines in biology and medi-
cine [1]. Over the years, new journals have been launched
to fulfil a particular research need (BMC Veterinary Re-
search 2005, BMC Systems Biology 2007 and BMC Psych-
ology 2013 are among such examples). All the biology
journals within the BMC series operate traditional an-
onymous peer review, where the authors do not know
who the reviewers are. However, the medical journals were
established with open peer review, where the identity of
the reviewers is known to all parties – editors, authors
and readers [2].
Two years ago the pharmacology titles in the BMC
series, BMC Pharmacology (a biology journal) and BMC
Clinical Pharmacology (a medical journal), joined forces
under the new title BMC Pharmacology and Toxicology
[3]. The combined journal retained the full scopes of the
original titles while also expanding to explicitly include
the field of toxicology. Many of the original Editorial
Board Members remained associated with the journal,
and new academics and clinicians also joined.
In merging a biology journal operating anonymous
peer review with a medical journal operating open peer
review, we debated what the peer review process should
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unless otherwise stated.the journal naturally retained the open peer review pol-
icy previously adopted by BMC Clinical Pharmacology –
in keeping with all the other medical titles in the BMC
series. BMC Cancer, another journal in the BMC series
with biology and medicine disciplines, also operates
open peer review.
Under open peer review, authors know who reviewed
their manuscript (reviewer reports are signed) and, if the
manuscript is published, the reader will also see the re-
viewers’ comments and the authors’ response. These
comments are published as part of the ‘pre-publication
history’ accompanying the published article, which also
contains all versions of the manuscript and (where rele-
vant) editors’ comments. By making the peer review
process completely transparent we aim to reduce the
competing interests that can occur especially for a jour-
nal which frequently publishes research sponsored by
pharmaceutical companies [4]. See this recent article [5]
for an example of a pre-publication history [6].
While many have recently discussed the benefits of open
peer review including transparency, accountability and
giving credit to reviewers [7-11], there are challenges too.
Potential reviewers may be more likely to decline to re-
view [12] and some (junior) reviewers may be reluctant to
sign a critical report [13,14]. There are field-specific differ-
ences too. Medical disciplines with the particular need to
be transparent about treatments for patients and compet-
ing interests appear to be more willing to embrace open
peer review than the biological sciences. However, within
biology there are differences between research fields, too:Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Table 1 Survey questions to the BMC Pharmacology &
Toxicology Editorial Board
Number Questions
1. Is your area of expertise in medicine or biology?
If medicine, are you a clinical academic or full time academic?
2. How many years have you been working as an academic?
3. Choose one that best describes you:
I was on the original board of BMC Clinical Pharmacology
I was on the original board of BMC Pharmacology
I joined the editorial board of BMC Pharmacology
and Toxicology within the last 2 years.
4. As an author, have you published in an open peer review
journal? (meaning that the reviewers’ identity was revealed
to you as an author)
4a (if yes) Do you think reports were less/equally/more useful
to you than those from a closed peer review journal? If you
have never published in a closed peer review journal please
go to the next question.
4b (if no) Would you consider publishing in an open
peer review journal? (if no, why?)
5. As a reviewer which peer review system do you prefer,
and why?
5a Open (authors and reading public know reviewers’ identity)
5b single-blind (i.e. reviewers know authors’ identity but
not vice versa)
5c double-blind (i.e. authors and reviewers do not know
each other’s identity)
6. As a handling editor do you prefer a different
(from your answer to question 5) model of peer review?
6a (If yes), which model do you prefer and why do you have
a different preference as an editor compared to as a reviewer?
7. As a reader do you look at the pre-publication histories on
BMC Pharmacology and Toxicology (or any of the open peer
review journals in the BMC series)?
7a If no, why not?
7b If yes, what is your main reason for looking at the
pre-publication history?
8. Do you have any further comments on open peer review?
Table 2 Definitions of open, single-blind and
double-blind peer review as operated by BioMed Central
Open peer review Editors, authors and reviewers know each
other’s identity. If the manuscript is published,
the reviewer reports, any editors’ comments,
authors’ response and all versions of the
manuscript are available via an accompanying
‘pre-publication history’.
Single-blind peer review Reviewers know authors’ identity but
not vice versa.
Double-blind peer review Authors and reviewers do not know each
other’s identity
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nities seem to accept open peer review more readily
than traditional subjects such as immunology and physi-
ology [15]. Perhaps this reflects their familiarity with
features of open-source software and social-networking
technologies [16].
At the time of the merger of BMC Pharmacology and
BMC Clinical Pharmacology, we said that we would report
on our findings of open peer review with the resulting bio-
medical journal. So, two years down the line, how have
things fared with BMC Pharmacology and Toxicology?
Our survey says…
The Editorial Board Members on BMC Pharmacology &
Toxicology represent a broad demographic from which
to solicit views on open peer review given their variety
of expertise in biology and clinical disciplines. Therefore,
we surveyed the current members of the Editorial Board
with eight questions (see Table 1). These covered their
particular expertise and whether they preferred one sys-
tem of peer review over another as an author, reviewer,
or handling editor. Table 2 gives a summary of the main
systems of peer review that were included for the pur-
pose of this survey. We also asked whether our Editors
read the pre-publication histories which accompany
published articles. Finally, any other comments on open
peer review were welcomed.
Of the 83 Editorial Board Members approached we re-
ceived 37 replies (a response rate of 45%). Half the re-
plies were from medics (of whom a third were practicing
clinicians) and half were from non-medical fields includ-
ing biology, chemistry and pharmaceutical sciences. The
anonymised answers are provided in Additional file 1.
It is clear that the Editorial Board Members who did
respond were consistent in that, regardless of their po-
tential role as ‘author’, ‘reviewer’ or ‘editor’, they prefer
the same system of peer review. It was not the case that
Editorial Board Members preferred one type of peer re-
view system in their role as editor, and another in their
role as reviewer (for example). Somewhat surprisingly,
the majority of Editorial Board Members preferred double-
blind peer review over open peer review (see Figure 1).
Among the reasons put forward in support of double-blind
peer review was the fact that this was perceived to be the
most objective system and thus minimized bias. However,
Editorial Board Members appreciated that it may not be
very effective in practice as it may be possible to infer from
the methods used, or reference list, who the authors are.
Although some Editorial Board Members recognised
the value of open peer review, commenting that it is
more egalitarian, increasing accountability and transpar-
ency, it was felt that open peer reviews may be more diffi-
cult for early career researchers to provide - as has been
noted again recently [17]. Our survey suggested that themore early career researchers preferred double-blind peer
review while the more senior Editorial Board Members
preferred single-blind or double-blind models (Figure 2).
In their role as authors, approximately half of the Edi-









Figure 1 Piechart of the responses received from the Editorial
Board to the question: ‘As a reviewer which peer review






no answer provided (green)
Figure 3 Piechart of the responses received from the Editorial
Board to the question: ‘As an author, have you published in an
open peer review journal?’
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ceived during an open peer review process were equally
useful to those received under anonymous peer review.
However, in previous research [18] we have found that the
quality of reports received was slightly higher under open
peer review than anonymous peer review. Reviewers
under an open peer review system provided more feed-
back on the methods, more constructive comments on
the content and substantiated their feedback better with
explicit evidence [18].
Finally, approximately half of the respondents of this
survey read the pre-publication history which accompan-
ies open peer reviewed articles in the BMC series, includ-
ing BMC Pharmacology and Toxicology (see Figure 4).
The pre-publication history contains all versions of the
manuscript, named reviewer reports, author responses
and (where relevant) editors’ comments. Of those Editorial
Board Members who reported that they did not look at
the pre-publication history, many simply had no time or
inclination to do so or wanted to judge an article on its
own merits. Some simply did not appreciate this informa-

















years of academic experien
Figure 2 Diagram of the preferences for a given peer review model cdid so in order to determine the scientific and ethical cre-
dentials of the reviewers and for further insights into peer
review.
The survey has provided a sample of the views and ex-
periences of academics and clinicians with respect to
peer review on a biomedical journal, and as a result we
appreciate there are improvements which can be made.
However, this small survey has some limitations too.
The low response rate limits the generalizability of the
findings; we were not able to draw any specific conclu-
sions reflecting (for example) the attitudes of particular
groups based on gender/subject background/seniority
towards different systems of peer review.
What next?
So two years into the open peer review experiment on
BMC Pharmacology and Toxicology, will we continue to
operate an open peer review system? Put simply: yes.
Among the Editorial Board Members who responded
to our survey, there appears to be an overall preference
for a peer review system that is double-blind (where au-
thors and reviewers are not revealed to each other).













no answer provided (green)
Figure 4 Piechart of the responses received from the Editorial
Board to the question: ‘As a reader do you look at the pre-
publication histories on BMC Pharmacology and Toxicology (or
any of the open peer review journals in the BMC series)?’
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genuine feeling among researchers or rather ‘wishful
thinking’ that double-blind peer review intuitively seems
the fairest approach [21]. Certainly not many biology
and medical journals operate double-blind peer review
and from a pragmatic view point it is difficult to prevent
reviewers from guessing who the authors are.
We will continue with open peer review at BMC
Pharmacology and Toxicology because of the ethical
grounds for doing so [2] and because the potential bene-
fits outweigh the negatives [22,23]. Open peer review
provides a fully transparent pre-publication history, and
the reading public can see who reviewed the manuscript
and what was said. Having access to peer reviews also
provides valuable information for training purposes [24,25]
and allows further research into the benefits of peer review
[26]. And by making peer review completely open and re-
viewers (and editors) accountable, we aim to reduce the
competing interests that can occur. But perhaps more rele-
vant, in this era of ‘predatory publishers’ [27] and ‘sting’ op-
erations [28] open peer review ensures that the decision-
making process is fully transparent for all to see.
From the feedback we receive more generally from au-
thors on our open peer review journals in the BMC
series, many value the helpfulness, quality and detail of
the reports. But given the responses received from our
Editorial Board Members we need to make more of the
fact that the pre-publication history is provided for
readers and what it contains.
If you have any further feedback on the open peer review
policy operated by BMC Pharmacology and Toxicology
we’d certainly welcome your comments.Additional file
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